April 30th 2024
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Review of Myelodysplastic Syndromes Aids Experts in Diagnosing and Treating Patients
December 27th 2022In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.
Read More
Treating Elderly Patients With ALL Remains a Challenge for Oncologists
December 16th 2022In an interview with Targeted Oncology, Marlise Luskin, MD, MSCE, discussed the challenges of treating adult and elderly patients with acute lymphoblastic leukemia and where new research in the space is headed.
Read More